Format

Send to

Choose Destination
Immunology. 2019 Apr 29. doi: 10.1111/imm.13064. [Epub ahead of print]

Regulation of regulatory T cells in cancer.

Author information

1
CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.
2
Laboratory of Lymphocyte Signalling and Development, The Babraham Institute, Cambridge, UK.

Abstract

The inflammatory response to transformed cells forms the cornerstone of natural or therapeutically induced protective immunity to cancer. Regulatory T (Treg) cells are known for their critical role in suppressing inflammation, and therefore can antagonize effective anti-cancer immune responses. As such, Treg cells can play detrimental roles in tumour progression and in the response to both conventional and immune-based cancer therapies. Recent advances in our understanding of Treg cells reveal complex niche-specific regulatory programmes and functions, which are likely to extrapolate to cancer. The regulation of Treg cells is reliant on upstream cues from haematopoietic and non-immune cells, which dictates their genetic, epigenetic and downstream functional programmes. In this review we will discuss how Treg cells are themselves regulated in normal and transformed tissues, and the implications of this cross talk on tumour growth.

KEYWORDS:

cancer; chemokine/chemokine receptors; cytokines/cytokine receptors; regulatory T cells; tumour immunology

PMID:
31032905
DOI:
10.1111/imm.13064

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center